China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE: 600062)
Health Care · Pharmaceuticals · CN
CN¥15.67
-2.06% today · -23.0% 1Y
China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE: 600062) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.41B and employs 13,184 people.
Over the last twelve months the share price has lost 23.0%, trading between 15.29 and 20.50.
Tweenvest scores China Resources Double-Crane Pharmaceutical Co.,Ltd. across four factors: quality 87/100, value 72/100, growth 40/100, dividend 72/100. Its strongest factor is quality.
600062 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.41B
- Revenue (TTM)
- $1.59B
- P/E
- 10.05
- EPS
- 1.56
- Dividend yield
- 3.06%
- Beta (5Y)
- -0.07
- 52-week high
- CN¥20.50
- 52-week low
- CN¥15.29
- Avg volume (3M)
- —
- Shares outstanding
- 1.03B
- Employees
- 13,184
- Next earnings
- —
About China Resources Double-Crane Pharmaceutical Co.,Ltd.
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
- ISIN
- CNE000000Q94
- Founded
- 1939
- Listed since
- May 22, 1997
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.